Indeed, as APPs may alleviate symptoms of schizophrenia through Wnt signaling pathway mediated by D2 dopamine receptor (Sutton et al., 2007), our results emphasize the potential pharmacogenetical and clinical relevance of TCF7L2 for antipsychotic-induced metabolic dysfunction in schizophrenia and provide a novel mechanism of TCF7L2 in antipsychotic-induced metabolic disturbance. This evidence concerns the gene DRD2 and schizophrenia.